In the last 10 years, novel treatment strategies that facilitate a personalized approach for AML have been widely investigated in (pre-)clinical studies and clinical trials (e.g., FLT3 inhibitors, a combination of hypomethylating agents and Venetoclax, CPX 351, and IDH1/IDH2 inhibitors) [4]. Here, FLT3 is linked to acute myeloid leukemia.